Australia's most trusted
source of pharma news
Friday, 01 May 2026
Posted 1 May 2026 PM
PBS listings have almost ground to a halt with only three additions to the scheme this month, compared to 17 in April and 12 in March.
Actor Pharmaceuticals had the biggest showing with Axhidrox listed on the PBS for primary axillary hyperhidrosis (PAHH) and Actobet listed for chronic stable plaque type psoriasis vulgaris. Both medicines were recommended at the PBAC’s November 2025 meeting.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.